Equities

Satellos Bioscience Inc

Satellos Bioscience Inc

Actions
  • Price (USD)0.381
  • Today's Change0.00 / 0.00%
  • Shares traded21.04k
  • 1 Year change+17.59%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 16:57 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast in CAD

The one analyst offering a 12 month price target expects Satellos Bioscience Inc share price to rise to 1.50 in the next year from the last price of 0.381.
High294.6%1.50
Med294.6%1.50
Low294.6%1.50

Earnings history & estimates in CAD

On Aug 12, 2024, Satellos Bioscience Inc reported 2nd quarter 2024 losses of -0.05 per share. This result was in line with the expectation of the one analyst following the company and was the same as last year's 2nd quarter results.
Average growth rate-22.44%
Satellos Bioscience Inc reported annual 2023 losses of -0.18 per share on Mar 27, 2024.
Average growth rate+25.00%
More ▼

Revenue history & estimates in CAD

-32768 did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.